Literature DB >> 24309072

Effect of chemodenervation of the rectus femoris muscle in adults with a stiff knee gait due to spastic paresis: a systematic review with a meta-analysis in patients with stroke.

Martin J Tenniglo1, Marc J Nederhand2, Erik C Prinsen3, Anand V Nene2, Johan S Rietman4, Jaap H Buurke4.   

Abstract

OBJECTIVE: To determine the effect of motor branch block (MBB) or neuromuscular block (NMB) of the rectus femoris on knee kinematics during swing, functional outcome, and energy cost in adults with spastic paresis presenting a stiff knee gait. DATA SOURCES: PubMed, Embase, CINAHL, and Cochrane Library were searched. Studies were collected up to February 26, 2013. Reference lists were additionally scrutinized. STUDY SELECTION: No restrictions were applied regarding study design. Patients were adults suffering from a central neurological disorder. Interventions had to include MBB or NMB. Outcome measures had to include knee kinematics during the swing phase. Study selection was independently performed by 2 reviewers. DATA EXTRACTION: Two reviewers independently assessed the methodological quality of included studies. Data on kinematics, functional outcome, and energy cost from patients with stroke were extracted from the total population and when possible pooled. DATA SYNTHESIS: A total of 9 articles describing 12 different studies were included. Knee kinematics (peak knee flexion or knee range) during swing improved significantly in all the included studies. The average increase in peak knee flexion varied from 1.9° to 15.4°. Data pooling of peak knee flexion in patients with stroke showed a significant improvement of 7.37° (P=.000) in NMB studies and of 9.35° (P=.002) in MBB studies. Data pooling of knee velocity at toe-off showed a significant improvement of 53.01°/s in NMB studies. In MBB studies, this improvement was not significant. Data pooling of knee range of motion, functional outcomes, and energy cost showed no significant difference.
CONCLUSIONS: According to this review, chemodenervation of the rectus femoris shows a significant improvement in peak knee flexion during swing. The effect on functional outcomes and energy cost is still unclear.
Copyright © 2014 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Botulinum toxins; Gait; Nerve block; Quadriceps muscle; Rehabilitation; Stroke

Mesh:

Substances:

Year:  2013        PMID: 24309072     DOI: 10.1016/j.apmr.2013.11.008

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  6 in total

1.  Muscle contributions to pre-swing biomechanical tasks influence swing leg mechanics in individuals post-stroke during walking.

Authors:  Lydia G Brough; Steven A Kautz; Richard R Neptune
Journal:  J Neuroeng Rehabil       Date:  2022-06-03       Impact factor: 5.208

2.  The Use of Botulinum Toxin for Treatment of Spasticity.

Authors:  Sheng Li; Gerard E Francisco
Journal:  Handb Exp Pharmacol       Date:  2021

Review 3.  Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity.

Authors:  Andrea Santamato
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-27       Impact factor: 2.570

4.  Post-stroke Hemiplegic Gait: New Perspective and Insights.

Authors:  Sheng Li; Gerard E Francisco; Ping Zhou
Journal:  Front Physiol       Date:  2018-08-02       Impact factor: 4.566

5.  The Effects of Botulinum Toxin Injections on Spasticity and Motor Performance in Chronic Stroke with Spastic Hemiplegia.

Authors:  Yen-Ting Chen; Chuan Zhang; Yang Liu; Elaine Magat; Monica Verduzco-Gutierrez; Gerard E Francisco; Ping Zhou; Yingchun Zhang; Sheng Li
Journal:  Toxins (Basel)       Date:  2020-07-31       Impact factor: 4.546

6.  Does the Duncan-Ely test predict abnormal activity of the rectus femoris in stroke survivors with a stiff knee gait?

Authors:  Martin J B Tenniglo; Marc J Nederhand; Judith F Fleuren; Johan S Rietman; Jaap H Buurke; Erik C Prinsen
Journal:  J Rehabil Med       Date:  2022-01-03       Impact factor: 3.959

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.